Paul Tudor Jones’s Recursion Pharmaceuticals RXRX Stock Holding History

Paul Tudor Jones’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.59M	Buy	+433,600	New	+$1.44M	﹤0.01%	2102

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Paul Tudor Jones's RXRX Position: Q2 2026 in Review

Paul Tudor Jones sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 265,296 shares — an estimated $883K sold.

Paul Tudor Jones first reported a position in RXRX in Q1 2022 and held it in 3 quarters. The position peaked at $814K in Q1 2026. 339 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Paul Tudor Jones reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Paul Tudor Jones sold 265,296 Recursion Pharmaceuticals shares in Q2 2026, an estimated $883K.
Paul Tudor Jones first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 3 quarters.
Paul Tudor Jones's Recursion Pharmaceuticals position peaked at $814K in Q1 2026.
339 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.